🟠 The primary endpoint, forced expiratory volume in 1 second (#FEV1), showed a mean treatment difference of 0.2% favoring noninferiority in both trials (Pnoninferiority &lt; .0001). 
#CRISPR #biotech $VRTX $NTLA $PRME $EDIT @FDA